Oxford BioMedica Announces Presentation Of New Clinical Data From ProSavin® Phase I/II Study in Parkinson’s Disease
— Six-month data from third cohort presented at ASGCT 14th Annual Meeting —— Highest efficacy results to date with 43% average motor function improvement —… Read More